Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 15, 2016 - Issue 7
Submit an article Journal homepage
341
Views
15
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation

Francesca Romana PonzianiInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, Italy
,
Silvia PecereInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, Italy
,
Loris LopetusoInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, ItalyCorrespondence[email protected]
,
Franco ScaldaferriInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, Italy
,
Giovanni CammarotaInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, Italy
&
Antonio GasbarriniInternal Medicine and Gastroenterology Division, A. Gemelli Hospital Rome, Rome, Italy
Pages 983-991 | Received 17 Feb 2016, Accepted 03 May 2016, Published online: 23 May 2016

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Akhil Munjal, Bhavtosh Dedania & Brooks D. Cash. (2020) Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 21:1, pages 63-71.
Read now

Articles from other publishers (14)

Antonio Nesci, Claudia Carnuccio, Vittorio Ruggieri, Alessia D’Alessandro, Angela Di Giorgio, Luca Santoro, Antonio Gasbarrini, Angelo Santoliquido & Francesca Romana Ponziani. (2023) Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship. International Journal of Molecular Sciences 24:10, pages 9087.
Crossref
Anna Piccin, Marco Gulotta, Stefano di Bella, Paola Martingano, Lory Saveria Crocè & Mauro Giuffrè. (2023) Diverticular Disease and Rifaximin: An Evidence-Based Review. Antibiotics 12:3, pages 443.
Crossref
Jing Liu, Lingyu Jiang, Jingju Zhang, Huili Huang, Xiubo Li & Fei Xu. (2021) Residue of Rifaximin in Milk of Lactating Dairy Cows Following Administration of Intrauterine Infusion. IOP Conference Series: Earth and Environmental Science 697:1, pages 012001.
Crossref
Rashmi Singh, Rashmi Prakash & Wim Dehaen. 2021. 319 410 .
Beatrice Campanella, Tommaso Lomonaco, Edoardo Benedetti, Massimo Onor, Riccardo Nieri & Emilia Bramanti. (2020) Validation and Application of a Derivatization-Free RP-HPLC-DAD Method for the Determination of Low Molecular Weight Salivary Metabolites. International Journal of Environmental Research and Public Health 17:17, pages 6158.
Crossref
Antonio Tursi, Carmelo Scarpignato, Lisa L. Strate, Angel Lanas, Wolfgang Kruis, Adi Lahat & Silvio Danese. (2020) Colonic diverticular disease. Nature Reviews Disease Primers 6:1.
Crossref
Beatrice Campanella, Massimo Onor, Tommaso Lomonaco, Edoardo Benedetti & Emilia Bramanti. (2019) HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Analytical and Bioanalytical Chemistry 411:28, pages 7551-7562.
Crossref
Laura Obici & Ole B. Suhr. (2019) Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research 29:S1, pages 55-63.
Crossref
Fernando Rizzello, Chiara Ricci, Michela Scandella, Elena Cavazza, Elisabetta Giovanardi, Maria Chiara Valerii, Massimo Campieri, Antonietta Comparone, Luigia De Fazio, Marco Candela, Silvia Turroni & Enzo Spisni. (2018) Dietary geraniol ameliorates intestinal dysbiosis and relieves symptoms in irritable bowel syndrome patients: a pilot study. BMC Complementary and Alternative Medicine 18:1.
Crossref
Jasmohan S. Bajaj, Giovanni Barbara, Herbert L. DuPont, F. Mearin, Antonio Gasbarrini & Jan Tack. (2018) New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Digestive and Liver Disease 50:8, pages 741-749.
Crossref
P. C. Konturek & Yurdagül Zopf. (2017) Therapeutische Modulation der Darmmikrobiota beim ReizdarmsyndromTherapeutic modulation of intestinal microbiota in irritable bowel syndrome. From probiotics to fecal microbiota therapy. MMW - Fortschritte der Medizin 159:S7, pages 1-5.
Crossref
Francesca Romana Ponziani, Maurizio Pompili & Antonio Gasbarrini. (2017) Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. Digestive Diseases and Sciences 62:9, pages 2220-2222.
Crossref
Rustam Aminov. (2017) History of antimicrobial drug discovery: Major classes and health impact. Biochemical Pharmacology 133, pages 4-19.
Crossref
Francesca Romana Ponziani, Maria Assunta Zocco, Francesca D’Aversa, Maurizio Pompili & Antonio Gasbarrini. (2017) Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World Journal of Gastroenterology 23:25, pages 4491.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.